Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ImmunoPET imaging of TIGIT in the glioma microenvironment.
Vincze SR, Jaswal AP, Frederico SC, Nisnboym M, Li B, Xiong Z, Sever RE, Sneiderman CT, Rodgers M, Day KE, Latoche JD, Foley LM, Hitchens TK, Frederick R, Patel RB, Hadjipanayis CG, Raphael I, Nedrow JR, Edwards WB, Kohanbash G. Vincze SR, et al. Among authors: sneiderman ct. Sci Rep. 2024 Mar 4;14(1):5305. doi: 10.1038/s41598-024-55296-y. Sci Rep. 2024. PMID: 38438420 Free PMC article.
TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I, Kumar R, McCarl LH, Shoger K, Wang L, Sandlesh P, Sneiderman CT, Allen J, Zhai S, Campagna ML, Foster A, Bruno TC, Agnihotri S, Hu B, Castro BA, Lieberman FS, Broniscer A, Diaz AA, Amankulor NM, Rajasundaram D, Pollack IF, Kohanbash G. Raphael I, et al. Among authors: sneiderman ct. Front Immunol. 2021 May 7;12:637146. doi: 10.3389/fimmu.2021.637146. eCollection 2021. Front Immunol. 2021. PMID: 34025646 Free PMC article.
Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.
Nisnboym M, Vincze SR, Xiong Z, Sneiderman CT, Raphael RA, Li B, Jaswal AP, Sever RE, Day KE, LaToche JD, Foley LM, Karimi H, Hitchens TK, Agnihotri S, Hu B, Rajasundaram D, Anderson CJ, Blumenthal DT, Pearce TM, Uttam S, Nedrow JR, Panigrahy A, Pollack IF, Lieberman FS, Drappatz J, Raphael I, Edwards WB, Kohanbash G. Nisnboym M, et al. Among authors: sneiderman ct. Cancer Res Commun. 2023 Jul 6;3(7):1173-1188. doi: 10.1158/2767-9764.CRC-22-0434. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37426447 Free PMC article.
A single-cell atlas deconstructs heterogeneity across multiple models in murine traumatic brain injury and identifies novel cell-specific targets.
Jha RM, Rajasundaram D, Sneiderman C, Schlegel BT, O'Brien C, Xiong Z, Janesko-Feldman K, Trivedi R, Vagni V, Zusman BE, Catapano JS, Eberle A, Desai SM, Jadhav AP, Mihaljevic S, Miller M, Raikwar S, Rani A, Rulney J, Shahjouie S, Raphael I, Kumar A, Phuah CL, Winkler EA, Simon DW, Kochanek PM, Kohanbash G. Jha RM, et al. Neuron. 2024 Sep 25;112(18):3069-3088.e4. doi: 10.1016/j.neuron.2024.06.021. Epub 2024 Jul 16. Neuron. 2024. PMID: 39019041 Free article.
Transcriptomic observations of intra and extracellular immunotherapy targets for pediatric brain tumors.
Frederico SC, Raphael I, Nisnboym M, Huq S, Schlegel BT, Sneiderman CT, Jackson SA, Jain A, Olin MR, Rood BR, Pollack IF, Hwang EI, Rajasundaram D, Kohanbash G. Frederico SC, et al. Among authors: sneiderman ct. Expert Rev Clin Immunol. 2024 Nov;20(11):1411-1420. doi: 10.1080/1744666X.2024.2390023. Epub 2024 Aug 18. Expert Rev Clin Immunol. 2024. PMID: 39114885
CD200 depletion in glioma enhances antitumor immunity and induces tumor rejection.
Raphael I, Mujeeb AA, Ampudia-Mesias E, Sever RE, McClellan B, Frederico SC, Sneiderman CT, Mirji A, Daba A, Puerta-Martinez F, Nisnboym M, Edwards WB, Graner M, Moertel CL, Castro MG, Kohanbash G, Olin MR. Raphael I, et al. Among authors: sneiderman ct. bioRxiv [Preprint]. 2024 Sep 10:2024.09.08.611922. doi: 10.1101/2024.09.08.611922. bioRxiv. 2024. PMID: 39314283 Free PMC article. Preprint.
Assessment of anti-CD69 antibody therapy alone or in combination with anti-PD-1 in murine GBM.
Nisnboym M, Sneiderman CT, Jaswal AP, Xiong Z, Vincze SR, Sever RE, Zou H, Frederico SC, Agnihotri S, Hu B, Drappatz J, Pollack IF, Kohanbash G, Raphael I. Nisnboym M, et al. Among authors: sneiderman ct. Expert Rev Clin Immunol. 2024 Oct 14:1-9. doi: 10.1080/1744666X.2024.2412770. Online ahead of print. Expert Rev Clin Immunol. 2024. PMID: 39402706
Dual-labeled anti-GD2 targeted probe for intraoperative molecular imaging of neuroblastoma.
Rosenblum LT, Sever RE, Gilbert R, Guerrero D, Vincze SR, Menendez DM, Birikorang PA, Rodgers MR, Jaswal AP, Vanover AC, Latoche JD, Cortez AG, Day KE, Foley LM, Sneiderman CT, Raphael I, Hitchens TK, Nedrow JR, Kohanbash G, Edwards WB, Malek MM. Rosenblum LT, et al. Among authors: sneiderman ct. J Transl Med. 2024 Oct 15;22(1):940. doi: 10.1186/s12967-024-05728-0. J Transl Med. 2024. PMID: 39407274 Free PMC article.
MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression.
Azambuja JH, Yerneni SS, Maurer LM, Crentsil HE, Debom GN, Klei L, Smyers M, Sneiderman CT, Schwab KE, Acharya R, Wu YL, Ekambaram P, Hu D, Gough PJ, Bertin J, Melnick A, Kohanbash G, Bao R, Lucas PC, McAllister-Lucas LM. Azambuja JH, et al. Among authors: sneiderman ct. bioRxiv [Preprint]. 2024 Sep 27:2024.09.26.614808. doi: 10.1101/2024.09.26.614808. bioRxiv. 2024. PMID: 39386586 Free PMC article. Preprint.